Known targets — ChEMBL curated mechanism
ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A known ✓ | Q03164 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 8/20 | 0.58 |
| ▸ | DYRK1A | Q13627 | 6/20 | 0.36 |
| ▸ | GSK3B | P49841 | 4/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.36 |
| ▸ | WNT1 | P04628 | 1/20 | 0.35 |
| ▸ | HTR3A | P46098 | 2/20 | 0.34 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.34 |
| ▸ | HTR3B | O95264 | 1/20 | 0.34 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.34 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CLK2 | P49760 | 2/20 | 0.33 |
| ▸ | CLK3 | P49761 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL1542011 | 1.00 | CHRNA7 (0.58) | CHRNA7DYRK1AGSK3BCHRNB2CHRNA4 | |
| Fumaric Acid SCHEMBL1542012 | 1.00 | CHRNA7 (0.58) | CHRNA7DYRK1AGSK3BCHRNB2CHRNA4 | |
| SCHEMBL1542398 | 0.92 | CHRNA7 (0.68) | CHRNA7DYRK1AGSK3BCHRNB2CHRNA4 | |
| SCHEMBL1542401 | 0.92 | CHRNA7 (0.68) | CHRNA7DYRK1AGSK3BCHRNB2CHRNA4 | |
| Fumaric Acid SCHEMBL3179498 | 0.88 | CHRNA7 (0.58) | CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3 | |
| Fumaric Acid SCHEMBL3179489 | 0.88 | CHRNA7 (0.58) | CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3 | |
| Abt-107 SCHEMBL1542457 | 0.84 | CHRNA7 (0.83) | CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3 | |
| Abt-107 SCHEMBL1542724 | 0.84 | CHRNA7 (0.83) | CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3 | |
| Abt-107 SCHEMBL1542729 | 0.84 | CHRNA7 (0.83) | CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3 | |
| Abt-107 SCHEMBL1542455 | 0.84 | CHRNA7 (0.83) | CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2308875-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives as .alpha.7 nAChR modulators | Abbott Laboratories (US) | 2011-04-13 | — | — | EP | disclosed |
| US-7655657-B2 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBOTT LABORATORIES (US) | 2010-02-02 | — | — | US | disclosed |
| US-20080064703-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBVIE INC. | 2008-03-13 | — | — | US | disclosed |
| US-20070060588-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBOTT LABORATORIES | 2007-03-15 | — | — | US | disclosed |
| US-20050245531-A1 | 5-{6-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]pyridazin-3-yl}-1H-indole; attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease, senile dementia, AIDS dementia, Pick's Disease, dementia associated with Down's syndrome; alpha 7 nAChR ligands modulators | ABBOTT LABORATORIES | 2005-11-03 | — | — | US | disclosed |
| US-20050137204-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBOTT LABORATORIES | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060588-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | CHRNA1, CHRNA7, CHRNA2 | MEN1 4342/4885KMT2A 2389/4885CHRNA7 2/4885 |
| US-20080064703-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | IDO1, IDO2, HTR3C | MEN1 2223/4885KMT2A 1075/4885CHRNA7 144/4885 |
| US-20050137204-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | CHRNA1, CHRNA7, CHRNA2 | MEN1 4342/4885KMT2A 2389/4885CHRNA7 2/4885 |
| US-20050245531-A1 | 5-{6-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]pyridazin-3-yl}-1H-indole; attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease, senile dementia, AIDS dementia, Pick's Disease, dementia associated with Down's syndrome; alpha 7 nAChR ligands modulators | CHRNA7, CHRNA6, CHRNA10 | MEN1 4603/4885KMT2A 1606/4885CHRNA7 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.